Premature mortality risk in people with convulsive epilepsy: Long follow-up of a cohort in rural China

Grants

Funding Acknowledgements

We thank all the participants for their cooperation. We also wish to thank the local health workers in the different study sites of China for their help and support. This project was funded by the Chinese Ministry of Health and Stichting Epilepsie Instellingen Nederland. GSB and JWS are based at University College London Hospitals/University College London, which receives a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme. JWS is supported by the Dr Marvin Weil Epilepsy Research Fund.ZH serves on the editorial advisory boards of the Chinese Journal of Neurology; has received research support from the Chinese Ministry of Health and the China Association Against Epilepsy; and has been a commissioner of the neurology branch of the Chinese Medical Association. GSB's husband works for, and has shares in, GlaxoSmithKline. PK serves on the scientific advisory board of GSK, Pfizer, and UCB Pharma; speaker's bureau of GSK, Sanofi, and UCB Pharma; provides consultancy to Eisai and GSK; and receives research grants from Eisai, Johnson & Johnson, Pfizer, and UCB Pharma. JWS served on scientific advisory boards for GlaxoSmithKline, UCB, and Viropharma; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology and Epileptic Disorders; serves on the speaker's bureaus of UCB and GlaxoSmithKline; and has received research support from UCB, GSK, the National Institutes of Health (NIH), the European Union Seventh Framework Programme, the Wellcome Trust, World Health Organization (WHO), the National Epilepsy Funds of the Netherlands, and the Epilepsy Society. The other authors have no competing interests. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.